<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01904292</url>
  </required_header>
  <id_info>
    <org_study_id>WA28118</org_study_id>
    <secondary_id>2012-003490-26</secondary_id>
    <nct_id>NCT01904292</nct_id>
  </id_info>
  <brief_title>A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis</brief_title>
  <official_title>A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Systemic Juvenile Idiopathic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This open-label, multicenter study will evaluate the pharmacokinetics, pharmacodynamics, and
      safety of subcutaneously administered tocilizumab in participants with Systemic Juvenile
      Idiopathic Arthritis (sJIA). Participants with body weight less than (&lt;) 30 kilograms (kg)
      will receive subcutaneous (SC) tocilizumab dose every 2 weeks (Q2W) and participants with
      body weight greater than or equal to (&gt;=) 30 kg will receive weekly (QW), for 52 weeks.
      Tocilizumab was administered every 10 days until pre-planned interim analysis was performed
      and changed to Q2W in participants with body weight &lt;30 kg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 15, 2013</start_date>
  <completion_date type="Actual">June 13, 2017</completion_date>
  <primary_completion_date type="Actual">June 13, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Tocilizumab</measure>
    <time_frame>Age &lt;2 years: 0 hours(h) on Days(D) 0,84; on D5,14,42,70,85,88,98,182,266, 364. Weight &lt;30kg, Age&gt;=2 years: 0,6,12h on D0,84; on D2,5,14,42,56,70,86,87,88,90,98,182,266,364. Weight &gt;=30kg: 0,6,12h on D0, 91; on D2,4,7,14,28,56,92,93,95,96,98,182,266, 364</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Plasma Concentration (Cmax) of Tocilizumab</measure>
    <time_frame>Age &lt;2 years: 0h on D0,84; on D5,14,42,70,85,88,98,182,266,364. Weight &lt;30 kg, Age &gt;=2 years: 0,6,12h on D0,84; on D2,5,14,42,56,70,86,87,88,90,98,182,266,364. Weight &gt;=30 kg: 0,6,12h on D0, 91; on D2,4,7,14,28,56,92,93,95,96,98,182,266,364</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Minimum Plasma Concentration (Cmin) of Tocilizumab</measure>
    <time_frame>Weight &lt;30 kg: predose (0h) on Days 0 and 84. Weight &gt;= 30 kg: predose (0h) on Days 0 and 91</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Serum Interleukin-6 (IL6) Levels</measure>
    <time_frame>Age&lt;2 years: 0h on Days 0,84; Days 5,14,42,70,85,88,98,182,266,364. Weight &lt;30 kg, Age &gt;=2 years: 0,6,12h on Days 0,84; Days 2,5,14,42,56,70,86,87,88,90,98,182,266,364. Weight &gt;=30kg: 0,6,12h on Days 0,91;Days 2,4,7,14,28,56,92,93,95,96,98,182,266,364</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Soluble IL-6 Receptor (sIL-6R) Levels</measure>
    <time_frame>Age&lt;2 years: 0h on Days 0,84; Days 5,14,42,70,85,88,98,182,266,364. Weight &lt;30 kg, Age &gt;=2 years: 0,6,12h on Days 0,84; Days 2,5,14,42,56,70,86,87,88,90,98,182,266,364. Weight &gt;=30kg: 0,6,12h on Days 0,91;Days 2,4,7,14,28,56,92,93,95,96,98,182,266,364</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Serum C-Reactive Protein (CRP) Levels</measure>
    <time_frame>Age &lt;2years: Days 0,14,28,42,70,84,98,126, 154,182,210,238,266,294,322,350,364. Weight &lt;30 kg, Age &gt;=2years: Days 0,14,28,42,70, 98,126,154,182,210,238,266,294,322,350,364. Weight &gt;=30kg: Days 0,7,14,21,28,42, 56,70,84,91,95,96,98,182,266,294,322,350,364</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Serum Erythrocyte Sedimentation Rate (ESR)</measure>
    <time_frame>Age &lt;2years: Days 0,14,28,42,70,84,98,126, 154,182,210,238,266,294,322,350,364. Weight &lt;30 kg, Age &gt;=2years: Days 0,14,28,42,70, 98,126,154,182,210,238,266,294,322,350,364. Weight &gt;=30kg: Days 0,7,14,21,28,42, 56,70,84,91,95,96,98,182,266,294,322,350,364</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Percentage of Participants with Anti-Tocilizumab Antibodies</measure>
    <time_frame>Age &lt;2 years: Days 0, 84, 182, 266, 364. Weight &lt;30 kg, Age &gt;=2 years: Days 0, 84, 182, 266, 364. Weight &gt;=30 kg: Days 0, 91, 182, 266, 364</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Percentage of Participants with At Least 1 Adverse Event</measure>
    <time_frame>57 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Juvenile Idiopathic Arthritis</condition>
  <arm_group>
    <arm_group_label>Tocilizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SC dose of tocilizumab based on body weight; participants with &lt;30 kg will receive 162 milligrams (mg) of tocilizumab Q2W and those participants =&gt;30 kg will receive 162 mg of tocilizumab QW, for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Subcutaneous 162 mg dose QW or Q2W for 52 weeks</description>
    <arm_group_label>Tocilizumab</arm_group_label>
    <other_name>RoActemra/Actemra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of sJIA according to the International League of Associations for
             Rheumatology (ILAR) classification

          -  History of inadequate clinical response (in the opinion of the treating physician) to
             Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and corticosteroids

          -  If a participant has received previous treatment with any biologic agents other than
             tocilizumab, these must have been discontinued according to the timelines defined by
             protocol prior to the baseline visit

          -  Participants currently receiving tocilizumab by the intravenous (IV) route of
             administration and with well-controlled disease do not require a period of
             discontinuation of IV tocilizumab and should have their first dose of SC tocilizumab
             administered on the date that their next IV tocilizumab infusion would be due

          -  Concurrent treatment with Disease Modifying Anti-Rheumatic Drugs (DMARDs) including
             methotrexate (MTX), NSAIDs, and oral corticosteroids are permitted at the discretion
             of the investigator

          -  Participants of reproductive potential must be willing to use highly effective
             contraceptive methods

        Exclusion Criteria:

          -  Prior discontinuation of IV tocilizumab because of inadequate clinical response or
             safety events (including hypersensitivity)

          -  Participants with poorly controlled disease (in the opinion of the treating physician)
             despite current treatment with IV tocilizumab

          -  sJIA that is well controlled by any treatment agent other than tocilizumab (Juvenile
             Arthritis Disease Activity Score of 71 Joints [JADAS-71] less than or equal to [&lt;=]
             3.8 with no fever)

          -  Participants who are wheelchair-bound or bedridden

          -  Any other auto-immune, rheumatic disease, or overlapping syndrome other than sJIA

          -  Lack of recovery from recent surgery or an interval of &lt;6 weeks since surgery at the
             time of the screening visit

          -  Females who are pregnant, lactating, or intending to become pregnant during study
             conduct

          -  Any significant concurrent medical or surgical condition that would jeopardize the
             participant's safety or ability to complete the study

          -  Known Human Immunodeficiency Virus (HIV) infection or other acquired forms of immune
             compromise or inborn conditions characterized by a compromised immune system

          -  History of alcohol, drug, or chemical abuse within 6 months of screening

          -  Any active acute, subacute, chronic, or recurrent bacterial, viral, or systemic fungal
             infection or any major episode of infection requiring hospitalization or treatment
             during screening or treatment with IV antibiotics completed within 4 weeks of the
             screening visit or oral antibiotics completed within 2 weeks of the screening visit

          -  History of atypical tuberculosis (TB) or active TB requiring treatment within 2 years
             prior to screening visit

          -  Positive TB test at screening unless treated with anti-TB therapy for at least 4 weeks
             prior to receiving study drug

          -  History of reactivation or new onset of a systemic infection such as herpes zoster or
             Epstein-Barr virus within 2 months of the screening visit

          -  Hepatitis B surface antigen or hepatitis C antibody positivity or chronic viral or
             autoimmune hepatitis

          -  History of concurrent serious gastrointestinal disorders such as ulcer or inflammatory
             bowel disease, Crohn's disease, ulcerative colitis, or other symptomatic lower
             gastrointestinal conditions

          -  History of or current cancer or lymphoma

          -  Uncontrolled diabetes mellitus with elevated glycosylated hemoglobin

          -  Macrophage activation syndrome (MAS) within 3 months of the screening visit

          -  Inadequate hematologic, renal or liver function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Children's Hospital Research Institute</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center; 5E Clinical Trials Unit</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago; Division of Rheumatology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago;Department of Pediatrics</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60649</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center; Pediatric Rheumatology</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Children's Hospital; Divison of Pediatric Rheumatology; Department of Pediatrics</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children'S Hospital Medical Center; Division of Rheumatology</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Fndn</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah; Immunology/Rheumatology/Allergy</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gral de Niños Pedro Elizalde</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1270</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Ninos de la Santisima Trinidad; Reumatologia Infantil</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital; Paediatric Rheumatology</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Children'S Hospital; Paediatric Rheumatology</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas - FMUSP Ribeirao Preto; Pediatria - Imunologia e Reumatologia</name>
      <address>
        <city>Ribeirao preto.</city>
        <state>SP</state>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas - FMUSP; Instituto da Crianca - Reumatologia</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal de Sao Paulo - UNIFESP</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>22793-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Children'S Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children'S Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital For Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Bicêtre; Pediatrie Generale</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus; Virchow Klinikum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Freiburg Zentrum für Kinder- und Jugendmedizin; Pädiatrische Infektio- u. Rheumatologie</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik; Zentrum fuer Allgemeine Paediatrie und Neonatologie</name>
      <address>
        <city>Sankt Augustin</city>
        <zip>53757</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Ospedale Pediatrico Bambin Gesu - Dip. Di Medicina</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini-Ospedale Pediatrico IRCCS</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuovo Ospedale Pediatrico Meyer; Reumatologia - Clinica Pediatrica 1°</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil de México &quot;Federico Gomez&quot;; Rheumatology</name>
      <address>
        <city>Mexico</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliditer SA de CV</name>
      <address>
        <city>Miexico City</city>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Jose Eleuterio Gonzalez; Pediatria</name>
      <address>
        <city>Monterrey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;Scientific Research Institute of Rheumatology&quot; of russian Academy of Medical Sciences</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI Sceintific children health center RAMS</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan De Deu; Servicio de Reumatologia Pediatrica</name>
      <address>
        <city>Esplugas DE Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Niño Jesus, Servicio Reumatologia</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal ; Servicio de Reumatologia</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Paz; Unidad de Reumatologia Pediatrica</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Fe: Servicio de Reumatologia Pediatrica</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital For Children</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital; Somers Clinical Research Facility</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham Children's Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2013</study_first_submitted>
  <study_first_submitted_qc>July 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2013</study_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

